发明名称 MOLECULAR DIAGNOSTIC TEST FOR PREDICTING RESPONSE TO ANTI-ANGIOGENIC DRUGS AND PROGNOSIS OF CANCER
摘要 Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
申请公布号 US2017073761(A1) 申请公布日期 2017.03.16
申请号 US201515116641 申请日期 2015.02.09
申请人 ALMAC DIAGNOSTICS LIMITED 发明人 HARKIN Denis Paul;KENNEDY Richard;KEATING Katherine E.;MCCAVIGAN Andrena;HILL Laura A.;DEHARO Steve;DAVISON Timothy;PATTERSON Fionnuala;DONEGAN Sinead;JELLEMA Gera;GOURLEY Charlie
分类号 C12Q1/68 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method for selecting whether to administer an anti-angiogenic therapeutic agent to a subject, comprising: measuring the expression level(s) of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression level(s) of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated.
地址 Craigavon GB